MorphoSys AG, DE0006632003

MorphoSys AG, DE0006632003

26.10.2017 - 14:04:22

MorphoSys to Host Q3 2017 Conference Call on November 7, 2017

Planegg/Munich, Germany, October 26, 2017

MorphoSys to Host Q3 2017 Conference Call on November 7, 2017

MorphoSys AG (FSE: MOR; Prime Standard Segment, TecDAX) will publish its first nine months' 2017 results on November 7, 2017 at 7:00 am CET.

At 2:00 pm CET (1:00 pm GMT, 8:00 am EST), the Management Board of MorphoSys AG will host a public conference call and webcast to present MorphoSys's financial results for the first nine month of 2017 and provide further details on the Company's latest developments.  

Dial-in numbers (listen only):

Germany: +49 89 2444 32975

United Kingdom: +44 20 3003 2666

USA: +1 202 204 1514  

We request that you please dial in up to 10 minutes before the call to ensure a prompt start and a secure line.

The presentation slides and webcast link will be available at the Company's website at www.morphosys.com/conference-calls A slide-synchronized audio replay of the conference will also be available at the corporate website following the live event.About MorphoSys: MorphoSys is committed to developing exceptional new treatments for patients suffering from serious diseases. A leader in the field of therapeutic antibodies today, MorphoSys is driven by the ambition of creating the most valuable pipeline of biopharmaceuticals in the biotechnology industry. Based on its proprietary technology platforms, MorphoSys, together with its partners, has built a therapeutic pipeline of more than 110 programs in R&D, around a quarter of which is currently in clinical development. In its proprietary development segment, MorphoSys, alone or with partners, is developing new therapeutic candidates, mainly focusing on cancer and inflammation. In its partnered discovery segment, MorphoSys uses its technologies to discover new drug candidates for pharmaceutical partners and participates from the programs' further development success, through success-based payments and royalties. MorphoSys is listed on the Frankfurt Stock Exchange under the symbol MOR. For regular updates about MorphoSys, visit http://www.morphosys.com.  

HuCAL(R), HuCAL GOLD(R), HuCAL PLATINUM(R), CysDisplay(R), RapMAT(R), arYla(R), Ylanthia(R), 100 billion high potentials(R), Slonomics(R), Lanthio Pharma(R) and LanthioPep(R) are registered trademarks of the MorphoSys Group.  

This communication contains certain forward-looking statements concerning the MorphoSys group of companies. The forward-looking statements contained herein represent the judgment of MorphoSys as of the date of this release and involve risks and uncertainties. Should actual conditions differ from the Company's assumptions, actual results and actions may differ from those anticipated. MorphoSys does not intend to update any of these forward-looking statements as far as the wording of the relevant press release is concerned.  

For more information, please contact:MorphoSys AG

Anke Linnartz Head of Corporate Communications & IR

Jochen Orlowski Associate Director Corporate Communications & IR

Alexandra Goller Senior Manager Corporate Communications & IR

Tel: +49 (0) 89 / 899 27-404investors@morphosys.com

26.10.2017 Dissemination of a Corporate News, transmitted by DGAP - a service of EQS Group AG.The issuer is solely responsible for the content of this announcement.The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases. Archive at www.dgap.de

Language: English Company: MorphoSys AG Semmelweisstr. 7 82152 Planegg

Germany Phone: +49 (0)89 899 27-0 Fax: +49 (0)89 899 27-222 E-mail: investors@morphosys.com Internet: www.morphosys.com ISIN: DE0006632003 WKN: 663200 Indices: TecDAX Listed: Regulated Market in Frankfurt (Prime Standard); Regulated Unofficial Market in Berlin, Dusseldorf, Hamburg, Hanover, Munich, Stuttgart, Tradegate Exchange   End of News DGAP News Service

622593  26.10.2017 

@ dgap.de

Amazon wird sich schwarzärgern, aber …

… wir schenken Ihnen den Report „Börsenpsychologie - Markttechnik für Trader“ heute trotzdem kostenfrei. Normalerweise kostet der Report im Onlinehandel 39,99 Euro.

Sie können sich den genialen Report heute jedoch absolut kostenfrei sichern. Wir senden Ihnen den Report vollkommen KOSTENFREI zu.

Jetzt HIER klicken und dank richtigen Timing reich an der Börse werden!